IMPORTANT NOTICE | Mayberry Investments Limited is a cashless institution.

Mayberry Investments Limited is a cashless institution.
Please note that cash deposits into any Mayberry account held at commercial banks, whether made in-branch or via Automated Banking Machines (ABMs), are not accepted and will not be processed. For information on accepted payment methods, please contact your Investment Advisor.

XFUND reports 282% increase in six months net profit

August 15, 2023

Sagicor Real Estate X Fund LTD (XFUND) for the six months ended June 30, 2023 reported a 25% increase in Total Revenue totaling $4.27 billion compared to $3.42 billion in the corresponding period last year. Total Revenue for the second quarter had a 34% increase to close at $2.19 billion compared to $1.63 billion for the comparable quarter of 2022.

Hotel Revenue increased by 12% to $3.99 billion compared to $3.55 billion for the Six months ended June 30, 2022. Management noted, “Increases in hotel revenues and improvements in asset prices on its bond portfolio contributed positively to the Group’s performance. Double Tree Orlando continues to benefit from an uptick in guest spending and room rates as demand for leisure and business travels trend upwards when compared to the prior period.”

Higher interest-earning assets and higher interest rates resulted in Net capital gains on financial assets and liabilities amounting to $96.71 million (2022: Loss of $275.15 million).

Depreciation increased by 5% to close at $460.80 million (2022: $437.06 million), while Hotel Expenses increased by 13% from $2.53 billion in 2022 to $2.86 billion in the period under review. As a result, operating expenses for the Six months ended June 30, 2023 amounted to $3.69 billion, a 15% increase relative to $3.20 billion reported in 2022.

Operating Profit for the Six months ended June 30, 2023, amounted to $581.40 million, a 169% increase relative to $216.29 million reported in 2022. Operating Profit for the Second quarter amounted to $354.11 million (2022: Operating Loss of $9.20 million). Profit before tax totalled $581.40 million, a 169% increase from the corresponding period last year (2022: $216.29 million).

Taxation for the Six months ended June 30, 2023, amounted to $160.86 million, a 52% increase relative to $106.13 million reported in 2022. Taxation for the second quarter amounted to $72.34 million (2022: $62.26 million).

Net Profit from continuing operations for the Six months ended June 30, 2023 had a 282% increase to reach $420.55 million (2022: $110.16 million). Also, Net profit attributable to shareholders for the Six months amounted to $420.55 million, up from the $110.16 million reported in 2022. For the Second quarter, Net profit attributable to shareholders was $281.77 million (2022: Net Loss of $71.46 million).

Consequently, Earnings Per Share for the Six months amounted to $0.19 (2022: EPS: $0.05), while Earnings Per Share for the quarter totaled $0.13 (2022: LPS of $0.03). The twelve-month trailing EPS was $0.35 and the number of shares used in these calculations was 2,243,005,125.

Notably, XFUND’s stock price closed the trading period on August 15, 2023 at a price of $8.49 with a corresponding P/E ratio of 24.53x.

Balance Sheet Highlights

‘Property Plant and Equipment’ grew 17% to close at $16.55 billion (2022: $14.19 billion). Both ‘Current Financial Investments’ and ‘Non-Current Financial Investments’ increased by $1.45 billion and $1.20 billion, respectively.

Consequently, The company’s assets totalled $29.83 billion (2022: $25.37 billion). This increase was mainly due to, “excess cash earned being reinvested into securities purchased under resale agreement”, management noted.

Shareholder’s equity was $19.75 billion (2022: $16.50 billion), representing a book value per share of $8.81 (2022: $7.35).

 

Disclaimer:

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.

More Stories from the Market
shutterstock_148562033
June 25, 2026   JMMB Group Limited (JMMBGL) has advised that a connected party purchased 100,000 JMMBGL shares on June 24, 2026.   …
shutterstock_148562033
June 25, 2026   Consolidated Bakeries Jamaica Limited (PURITY) has advised that a director purchased 38,304 PURITY shares on June 22, 2026….
shutterstock_453968572
June 25, 2026   Future Energy Source Company Limited (FESCO) has advised that it has issued a 4-year corporate bond, with NCB Capital Marke…
MIL
June 25, 2026 Mayberry Jamaican Equities Limited (MJE) has advised that the daily Net Asset Value (NAV) for June 23, 2026, was J$8.60. MJE’s closin…
MIL
June 25, 2026 Mayberry Jamaican Equities Limited (MJE) has advised that the daily Net Asset Value (NAV) for June 22, 2026, was J$8.49. MJE’s closin…
MIL
June 25, 2026 Mayberry Jamaican Equities Limited (MJE) has advised that the daily Net Asset Value (NAV) for June 19, 2026, was J$8.71. MJE’s closin…
MIL
June 25, 2026 Mayberry Jamaican Equities Limited (MJE) has advised that the daily Net Asset Value (NAV) for June 18, 2026, was J$8.41. MJE’s closin…
MIL
June 25, 2026 Mayberry Jamaican Equities Limited (MJE) has advised that the daily Net Asset Value (NAV) for June 17, 2026, was J$8.56. MJE’s closin…